Truist Securities Maintains Buy on Intuitive Surgical, Lowers Price Target to $270
Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and lowers the price target from $355 to $270.
Here’s How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 15 Years
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 15 years by 12.24% on an annualized basis producing an average annual return of 18.51%. Currently, Intuitive Surgical has a market capitalization of $72.72 billion.
Check Out What Whales Are Doing With ISRG
A whale with a lot of money to spend has taken a noticeably bullish stance on Intuitive Surgical.
Looking at options history for Intuitive Surgical (NASDAQ:ISRG) we detected 13 strange trades.
$1000 Invested In Intuitive Surgical 10 Years Ago Would Be Worth This Much
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 2.63% on an annualized basis producing an average annual return of 14.43%. Currently, Intuitive Surgical has a market capitalization of $85.51 billion.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Shenzhen Edge Medical Seeks Place in China’s Surgical Robot Market
Key takeaways:
Shenzhen Edge Medical has applied for a Hong Kong IPO, following China’s approval for the sale of one of its key products in January
Company will face challenges from a growing number of domestic rival products already on the market
By Molly Wen
Morgan Stanley Maintains Equal-Weight on Intuitive Surgical, Lowers Price Target to $300
Morgan Stanley analyst Drew Ranieri maintains Intuitive Surgical (NASDAQ:ISRG) with a Equal-Weight and lowers the price target from $325 to $300.
55 Biggest Movers From Friday
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.